Rpg Life Sciences Limited · NSE:RPGLIFE
Rpg Life Sciences — 9M FY24 Earnings Presentation
40 slides from Rpg Life Sciences's earnings presentation, Feb 2, 2024
Slide 1: Cover letter to stock exchanges: Investor Presentation
RPG LIFE SCIENCES LIMITED L Regd. Off.: RPG House 463, Dr. Annie Besant Road Worli, Mumbai 400030, India Tel: +91-22-24981650 / 66606375 Fax:+91 -22-24970127 Email: info@rpglifesciences.com RPO LIFE SCIENCES www.rpglifesc iences.com CIN : L24232MH2007PLC169354 February 02 , 2024 To The Manager BSE L
Slide 2: Investors' Presentation 9M FY24
R?G LIFE SCIENCES An <>>>Rr1'G Company Investors' Presentation 9M FV24
Slide 3: Disclaimer
Disclaimer This presentation may include statements which may constitute forward-looking statements. All statements that address expectations or projections about the future, including, but not limited to, statements about the strategy for growth, business development, market position, expenditures,
Slide 4: RPG Group: One of India's fastest-growing diversified conglomerates
RPG Group: One of India's fastest-growing diversified conglomerates IUNLEASHTALENT RPG Group has a business history dating back to 1820 AD in banking, textiles, jute, and tea . RPG Enterprises was founded in 1979 and currently operates in various businesses TOUCH LIVES in Infrastructure, Technology,
Slide 5: RPG Life Sciences: An Integrated Pharmaceutical Company
RPG Life Sciences: An Integrated Pharmaceutical Company-APls to Formulations; R&D to Manufacturing to Marketing RPG Life Sciences, part of RPG Enterprises, is an integrated research based pharmaceutical Company operating in the domestic and international markets in the branded formulations, global g
Slide 6: RPG Life Sciences Product Portfolio
RPG Life Sciences Product Portfolio: Strong 'Textbook' brands being augmented by Diligent Life Cycle Management and New Launches in Chronic and Specialty therapies Key Therapies Le~ Portfolio New Portfolio Nephrology lmmunosuppressants Text Book Brands Specialty Chronic Rheumatology 'NuGlip.!iJ! {Ex
Slide 7: An ~» R?G Company L
An ~» R?G Company 6 L ~ G LIFE SCIENCES
Slide 8: Journey of RPG Life Sciences
Journey of RPG Life Sciences ~ ~ • Process Excellence! Business Processes Pro d u Ct Portfolio, Peop e, Fundamentals Fixation Sales Hygiene, People, Organization Sustainable Profitable Growth Revenues, Volumes, Margins Benchmark Performance Profitability, Leverage, Liquidity Ratios Scale-up An ~» R?
Slide 9: Q3 FY24 Performance
Q3 FV24 Performance (All figures in Rs. Crores except EPS in Rs.) Revenue from Operationsf EBITDA & EBITDA Margin PBT & PBT Margin 35.5 ~ 153.7 130.6 29.7 ~.,. ~39.8 1/g Q3 FV23 Q3 FY24 Q3 FV23 Q3 FY24 Q3 FV23 Q3 FY24 PAT & PAT Margin f EPS l 26.5 ~lo 16.0 19.1 ? ~ 11.6 Q3 FV23 Figures in circle are
Slide 10: 9M FY24 Performance
9M FV24 Performance (All figures in Rs. Crores except EPS in Rs.) Revenue from Operationsf EBITDA & EBITDA Margin PBT & PBT Margin 394.3 p 455.1 ~ 8 113.0 ~ 100.1 ·-89.7 --=,~. • 24.8% 77.9 B 9M FY23 9M FY24 9M FY23 9M FY24 9M FY23 9M FY24 PAT & PAT Margin f EPS l I 74.4 d\o 45.0 57.3 ;? - 34.6 / 9M
Slide 11: 9M FY24: Year Trends - Key Financials
9M FY24: 5 Year Trends- Key Financials (All figures in Rs. Crores except EPS in Rs.) Revenue from Operationsf EBITDA & EBITDA Margin f PBT & PBT Margin f 107.5 113.0 512.8 100.1 440.2 .,_ 455.1 89.4 91.7 330.2 375.6 389.1 70.8 73.2 59.9 -- 53.6 inn FY19 FY20 FY21 FY22 FY23 9M FY24 34.4 FY19 FY20 FY2
Slide 12: Trajectory of Uninterrupted Margins Expansion continues
9MFY24: SY Trajectory of Uninterrupted Margins Expansion continues despite Market Challenses EBITDA% PBT% 22.0% PAT% 16.4% 9.8% ,,,,,,,... 8.7% 4.2% ,cv.. 3.9% 3.9% 3.3% ~ -~ ~ ~ ◊ ~ ~ ~ rv' rv' ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ L Except 9M FY24, all other margin numbers are Full Year numbers 11 An ~» R
Slide 13: 5 Year Trends - Key Ratios (ROCE, ROE, D/E)
5 Vear Trends- Key Ratios (ROCE, ROE, D/E) ROCE% l ROE%f Debt/Equity Ratio l 0.22 20.9% 24.9% 28.5% 29.7% 16.4% 18.5% 20.1% 22.0% 9.7% 6.7% 0.06 FV19 FV20 FY21 FY22 FV23 FY19 FY20 FY21 FY22 FY23 FY19 FY20 - 0.01 FY21 0.00 FY22 0.00 FY23 Company continues to remain Debt-free An ~» R?G Company 12 L ~
Slide 14: 9M FY24: Business Segment-wise Performance
9M FV24: Business Segment-wise Performance Domestic Formulations contributed 66% to total sales of 9M FY24 • 16% sales growth driven by both Legacy and New products 256.7 ~ 298.2 • Growth consistently higher than the market Business Segments • New products* contribution improving consistently (curre
Slide 15: RPG Life Sciences ICRA Rating Reaffirmed in FY23
RPG Life Sciences ICRA Rating Reaffirmed in FV23 Long term rating reaffirmed at A Short term rating reaffirmed at A1 Outlook on long term rating has been retained as Stable The rating reaffirmation factors: ► Strong brands in the Indian Pharmaceutical Industry ► Considerable improvement in the opera
Slide 16: An ~» R?G Company L
An ~» R?G Company 15 L ~ G LIFE SCIENCES
Slide 17: Domestic Formulations (DF): Overview and Strategy
Domestic Formulations {DF): Overview and Strategy • Operating in Mass/Mass-specialty and Specialty segments • Presence in both Acute & Chronic therapy areas • Leading Text Book Brands - Azoran, Aldactone, Lomotil, Naprosyn, Serenace, Norpace • Leading player in lmmunosuppressant category • Good Cust
Slide 18: International Formulations (IF) Business: Overview and Strategy
International Formulations (IF) Business: Overview and Strategy • Strong presence in immunosuppressant segment (Azathioprine) • Footprints across Regulated and Emerging Markets - Canada, UK, Germany, France, Australia, South East Asia, Africa • Long lasting, impeccable supply track record and busine
Slide 19: APIs Business: Overview and Strategy
APls Business: Overview and Strategy • High value, low volume, niche APls • Footprints across geographies - LATAM, Germany, China, South • Mature stable molecules Korea, Iran, Bangladesh, Egypt, India, etc. • Provides backward integration to International • Strong customer focus - long-lasting relat
Slide 20: 1 ;1 j Et1aa, t41111£1:~ ;f;f; tt4 ;1. tiii ~iii ffl ITT t:t, L
I 1;1 jEt1aa, t41111£1:~ ;f;f; tt4 ;1. tiii ~iii ffl ITT t:t, An ~» R?G Company 19 L ~ G LIFE SCIENCES
Slide 21: Manufacturing Facilities
Manufacturing Facilities • Fl unit caters to the domestic and emerging markets • Multipurpose plant with dedicated product lines for oral dosage forms including tablets, liquids and powder • WHO, Kenya, Nigeria approved • F2 unit caters to the regulated markets • Dedicated product lines for oral dos
Slide 22: - ·- .c - a. "'C
...... N U) -·-.c- (I) .., ··- ca a. ca u "'C C (I) e Clj ~ u ca § cc 0 00 u C & ..,'-0 V) ~ ~ C: <:(
Slide 23: An ~» R?G Company L
An ~» R?G Company 22 L ~ G LIFE SCIENCES
Slide 24: Top Operational Highlights
Top 10 Operational Highlights ■ Strategic Asset (Mega Brand) building via a Comprehensive Life CyclE Legacy Product Naprosyn becomes the first 60 Cr+ Brand of the Company in FY23; On Management Strategy for DF Legacy products yielding results its way to becoming the 1st 100 Cr brand ■ Strategic Port
Slide 25: Digitalization Initiatives: Sales & Marketing
Glimpses of RPGLS Digitalization Initiatives: Sales & Marketing RxR 2.0 for 1' Salesforce Effectiveness; RPG Serv for 1'SoV and 1'Doctor Servicing RxR 2.0: RPGLS Salesforce Effectiveness Automation Tool RPG Serv: Anytime Anywhere Doctor Support Initiative 8 ' ., .. . ~ NephroCare X ■ < • A suite of
Slide 26: Digitalization Initiatives: Sales & Marketing (GenAI)
Glimpses of RPGLS Digitalization Initiatives: Sales & Marketing LSAI: Using GenAI for Superior Customer Servicing and impactful Marketing Gen .A l f,o,r P'hysiciarn Se:rvices '6e111 .Al for .Campaign Dashboards 11.h. °:Se{?. . • U. P:;:ilidt&:c-..,• i,41..'tQ !llti ffl;.i<l!D' -~ . ..... ,-:. ~ •· .
Slide 27: Digitalization Initiatives: Manufacturing and Quality Operations
Digitalization Initiatives: Manufacturing and Quality Operations Roadmap of >20 Initiatives under various stages of Implementation Digital Retina Intelligent Chilling IOT based AHU Power Management Scanner Plant Manager monitoring system System • Biometric Access with IRIS/ Retina • Implementation •
Slide 28: Innovation Culture @RPGLS
Innovation Culture @RPGLS 1' Revenue ~ Cost # of Innovation Projects: 26 (FY21) ➔ 105 (FY22) ➔ 27 (FY23) ➔ 201 (FY24) 1' Compliances NapRelief WOMAC Trial : One of the largest Mega Trials conducted in the industry (10200 patients; 458 Doctors; - 450 Centres- Naprosyn Gel) Customer-related Innovation
Slide 29: People Initiatives: Building Happy Performance focussed Culture
People Initiatives: Building Happy Performance focussed Culture I Love M_y Work I Feel Valued @ RPGLS Heroes Outperformance I am Growing ~ •• recognition t ~ We Skill. You Grow. Competency building -< ( ?ri1 You Excel. We Applaud. 0 continuum i~'I l'l '+-eel , ,:ie Motivation continuum tou •• Akanks
Slide 30: People Initiatives: Glimpses
People Initiatives: Building Happy Performance focussed Culture- Glimpses r -:- \ Hello Happiness Forums: Monthly Town hall for Connect, Recognition and Camaraderie l hello happiness JI Digital forum ~ ------------,,-,"' An ~» R?G Company ~ G LIFE SCIENCES
Slide 31: People Initiatives: Glimpses
People Initiatives: Building Happy Performance focussed Culture- Glimpses r:-==--~ Parivar Tyohar Utsav Shrankhla: Virtual Celebration of Festivals with Families i \ ' -~ ..~ g R ~===-~'_/ ' la. J.~ • • ,~ ~ ' ..i..4 . • · , ,,, ,-~ ~ -- • . ..__...,.,~ "" ,.liii ,._ _, I 1--.----,ei1~ An ~» R?G Com
Slide 32: People Initiatives: Glimpses
People Initiatives: Building Happy Performance focussed Culture- Glimpses ,.,--. 1Rewairdls & Re.oocgnitiom Hi-Fn~r Fu111ctio111 ,Em1p iovee engagemeint •C..vowdsourcung Ideas from field Foroe Employee Motivation: Happy Cards anlll Emaileir.s ... •• u lit!,IJ, ~ "'-- An ~» R?G Company ~ G LIFE SCIEN
Slide 33: An ~» R?G Company L
An ~» R?G Company 32 L ~ G LIFE SCIENCES
Slide 34: Recognized as India's Top 500 Value Creators by Dun & Bradstreet
RPG Life Sciences recognized as India's Top 500 Value Creators by Dun & Bradstreet dun &braod:s.l rooal ~~pi,ity ~ RPG Ut. Sai:1-1:n Llml1ad dllf'l&lh.-.ul:1lr= ',(500"'\, ,I- .,,,~fo~ ~.....-~rlP ~ aBMI i'~NfllfnriH!r ~ i1-- Compa.nies from acr,o.ss 52 sectors. An ~» R?G Company L ~ G LIFE SCIENCES
Slide 35: Jamnalal Bajaj Award for Fair Business Practices
RPG Life Sciences Awarded with 'Jamnalal Bajaj Award for Fair Business Practices' An ~» R?G Company L ~ G LIFE SCIENCES
Slide 36: Top Awards from IDMA
RPG Life Sciences Bagged Top Awards from IDMA An ~» R?G Company L ~ G LIFE SCIENCES
Slide 37: Naprosyn+ bags Brand Champion of the Year Award
New Launch Naprosyn+ bags Brand Champion of the Vear Award HIS SILVER IMPACT Naprosyn+ ,.,,fA#, &hall ~~~f>.NTO An ~» R?G Company L ~ G LIFE SCIENCES
Slide 38: Committed to our Transformation Agenda
We are Committed to our Transformation Agenda to continue our upward growth trajectory Profit Growth and Focus on Strong Governance Cashflows Building Domestic Formulations Business Continued diligent thrust on cost All operations within the via the identified 5 Pillars control measures both in Opex
Slide 39: The Journey Ahead: 7 Pillars to Scale-up business
The Journey Ahead: Diligent work on-going on 7 Pillars to "Scale-up" business 7 Pillars Identified 1 2 3 4 7 State-of-art Targeted Institutionalized ii :(Im~ C•U•X91 Talent 1' Capacity Niche- focus enablement Development INNOVATION PLANTS R&D PIPELINE /Acquisition • Focused New • lnstitutionalizat •
Slide 40: 04D04D0 0(D(!) An ~» R?G Company L
04D04D0 0(D(!) An ~» R?G Company ----------------------------------------------- L ~ G LIFE sc1ENCEs